WillItSurvive
Pharma and healthcare groups · subsidiary of Fosun International Limited · China

Fosun Pharma

en.fosunpharma.com ↗

Chinese drugmaker making generics, biosimilars, and licensed-out innovative drugs like GLP-1s.

Hard to displace
Assessed 30 July 2026 · Evidence as of 30 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 30 July 2026 · Checkable from August 2026 · Every call on the record Checkpoint: 1H2026 results release following profit alert
The call

Fosun Pharma sits on regulatory and manufacturing ground rivals cannot quickly copy, with growth now leaning on licensing deals like the Pfizer GLP-1 pact rather than AI or new entrants.

Fosun Pharma makes and sells medicines across China, India, and Africa, with approvals from Chinese, U.S., and European regulators. Big global rivals like Pfizer cannot easily copy its low-cost factories or Chinese government relationships, and it actually licenses drugs to Pfizer rather than fighting them directly. The real threat is not competition but the parent company's high debt load and new U.S. rules that could block Chinese drug makers from selling inventions abroad, which would dry up the cash that funds new medicines.

Why
01
AI pressure: None apparent. AI tools like Insilico speed up drug discovery inside Fosun's pipeline but cannot replace its approvals or factories. Could AI do the core job? Unlikely.
02
Bigger players: Pfizer, Roche, Novartis, AstraZeneca. These firms cannot easily copy Fosun's China regulatory access and manufacturing cost base, so Fosun licenses drugs to Pfizer instead of losing to it. Could a giant copy it? No, they are blocked.
03
What protects it. NMPA, FDA, and EMA approvals plus GMP plants across China, India, and Africa, tied to a Sinopharm distribution stake.
What would change this call
NMPA/FDA/EMA decision on Henlius HLX14 (denosumab biosimilar) NDA accepted Dec 2025. Approval or rejection tests whether Fosun's biosimilar pipeline can convert into revenue against rivals like Innovent and CSPC.
Fosun Pharma's 1H2026 results release versus the RMB1.5-1.8 billion profit guidance. A miss would signal margin pressure from VBP pricing outpacing R&D and licensing gains.
Any further US regulatory rejection of a China-pharma filing (following Hengrui's July 2026 FDA rejection) affecting Fosun's Henlius submissions. Would show Western regulatory risk is spreading across Chinese pharma outbound pipelines, not just Hengrui.
Key numbers
  • FY2025 revenue RMB 41.6B, up 1.4 to 1.9% YoY (2025-12-31)
  • FY2025 net profit RMB 3.371B, up 21.69% YoY (2025-12-31)
  • Pfizer deal: $150M upfront, up to $2.085B milestones (2025-12-09)
Named risks
  • Parent Fosun International could force capital extraction or distressed asset sales from Fosun Pharma amid rising debt maturity share. Severity: high
  • China Volume-Based Procurement pricing pressure limits domestic revenue growth to roughly 2 to 7% YoY. Severity: medium
  • US biosecurity actions or outbound licensing reviews could compress the value of the licensing pipeline strategy. Severity: medium
  • Sector-wide regulatory friction, illustrated by Hengrui's third FDA rejection in July 2026, signals elevated approval risk for Chinese pharma outbound deals. Severity: medium
  • Discrepancy between company-reported headcount (40,603) and third-party estimates (about 39,493) raises data reliability questions. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Jiangsu Hengrui Pharmaceuticalslosing toHengrui has 427 active drug programs and a $15.2 billion BMS out-licensing deal as of 2026, larger scale than Fosun's pipeline
PfizercontestingFosun licenses GLP-1 candidate YP05002 to Pfizer for $150 million upfront in December 2025 rather than competing directly
Hansoh Pharmaceuticallosing toHansoh share price rose over 90% in 2025 on rapid innovative drug approvals
CSPC Pharmaceutical GroupcontestingNamed alongside Fosun as a leading contender for Chinese pharma global expansion by analysts in 2026
Novo Nordisk and Eli LillycontestingFosun subsidiary Yao Pharma entered the GLP-1 obesity space via a December 2025 Pfizer licensing deal
Questions people ask
What is Fosun Pharma's biggest risk?
The main pressure comes from Chinese innovative biotech rivals such as Jiangsu Hengrui, Innovent Biologics, and Akeso, which compete hard for national drug list (NRDL) slots and oncology or biosimilar market share. NRDL price cuts also squeeze Fosun's generics margins, creating a steady, mid-level competitive squeeze rather than an acute crisis.
Is Fosun Pharma in financial trouble?
No major distress signals appear in the data: FY2025 revenue was RMB 41.662 billion with net profit attributable to shareholders of RMB 3.371 billion, as of 2025-12-30. Overseas revenue grew to 31.15% of total per a 2026-03-24 report, and Q1 2026 revenue rose 6.93% year over year, though a 2027-12 watch-item flags whether Fosun International may reduce its stake below 35% or divest another listed subsidiary.
Who are Fosun Pharma's biggest competitors?
Key domestic rivals include Jiangsu Hengrui, Innovent Biologics, and Akeso, which compete for NRDL slots and oncology or biosimilar market share. Within the same pharma cohort, Fosun sits below innovation-driven leaders like Jiangsu Hengrui and BeOne Medicines (BeiGene) in pipeline strength, while its Henlius biosimilars unit directly pressures originator biologics makers like Roche.
Is Fosun Pharma at risk from AI?
The risk from AI-driven drug discovery platforms like Insilico Medicine and XtalPi is rated 'building' rather than urgent, since these tools speed up rival pipelines but Fosun relies more on licensing deals than in-house AI R&D. Fosun's protection from AI-driven disruption rests on regulatory licensing, hospital assets, and manufacturing scale, assets that are hard for AI models or new entrants to reproduce quickly.
How does Fosun Pharma compare to other pharma companies overall?
Fosun Pharma is grounded in durable, hard-to-replicate assets such as regulatory approvals, factories, hospitals, and distribution networks, earning it a 'Hard to displace' standing. Within China's pharma cohort, though, it sits below innovation-driven leaders like Jiangsu Hengrui and BeOne Medicines (BeiGene) in pipeline strength, while its Henlius biosimilars unit directly pressures originator biologics makers like Roche.
What should I watch for with Fosun Pharma going forward?
By 2027-03, the company's overseas revenue share could exceed 35% of total in the FY2026 annual report, up from 31.15% as of the 2026-03-24 report. Separately, by 2027-12 there is a dated watch-item on whether Fosun International reduces its stake below 35% or divests another major listed subsidiary, alongside 2026 Phase 3 readouts for AR1001, HLX22, and DM1001 and an FDA decision on the HLX04 bevacizumab biosimilar.
Timeline
  • 2026-07-29Fosun International profit alert guides 1H2026 profit RMB 1.5 to 1.8 billion, up 127 to 172% YoY
  • 2026-07-20NMPA clears clinical trials for FXR-0906 targeting hypertriglyceridemia
  • 2026-06-20Insilico and Fosun identify QPCTL inhibitor preclinical candidate in under 40 days (vendor-claimed)
  • 2026-04-21Fosun Pharma files 2025 Annual Report with HKEX
  • 2026-04-01Fosun International holds 2025 annual results presentation, cites rising debt maturity share
  • 2026-03-24Fosun Pharma announces 2025 annual results, overseas revenue hits RMB 12.977 billion
  • 2026-03-20Henlius reports 2025 results, third consecutive profitable year
  • 2025-12-09Pfizer licenses oral GLP-1 candidate YP05002 from Yao Pharma for up to $2.235 billion
  • 2025-08Luvometinib gains Breakthrough Therapy Designation from Saudi FDA
  • 2024-06-18Fosun sells about 5% Gland Pharma stake for approximately $172 million
Head to head
Fosun Pharma vs Jiangsu Hengrui Pharmaceuticals
Revision history
30 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Vertex PharmaceuticalsTenet HealthcareIntuitive Surgical
More in Pharma and healthcare groups →
Sources